Having A History Of Heart Disease, Vice President Ma'ruf Is Waiting For The Palace Doctor's Recommendation To Vaccinate The Elderly

Vice President Ma'ruf Amin at the vice president's office in Jakarta (Photo: ANTARA)

JAKARTA - Vice President Ma'ruf Amin is waiting for a recommendation from the Presidential Team of Doctors regarding the injection of the COVID-19 vaccine made by Sinovac.

Vaccines for the elderly (Elderly) by the Food and Drug Administration (BPOM) are permitted to be used.

Spokesperson for the Vice President Masduki Baidlowi said, Vice President Ma'ruf was ready at any time to be injected with the COVID-19 vaccine as long as he received a recommendation from the Presidential Team of Doctors.

"The Vice President is ready (to be vaccinated) at any time, but that will be determined by the health team and the Presidential Team of Doctors. If the Team of Doctors declares that they are ready, the Vice President will be ready, if (suggested) no, yes not (vaccinated)," said Masduki. in Jakarta reported by Antara, Sunday, February 7.

Masduki added that the Presidential Team of Doctors had also been working to find the type of COVID-19 vaccine that was in accordance with Vice President Ma'ruf Amin's health condition.

Apart from being included in the elderly group, the Vice President also has a history of heart medication using a stent or ring.

"The Presidential Team of Doctors has moved, in terms of what the possibilities are, whether to follow Sinovac or follow other (vaccines)," he said.

Meanwhile, the BPOM has issued a permit for emergency use of the vaccine made by Sinovac, Coronavac, for groups of people over 60 years of age in Indonesia.

This permit was issued by the BPOM on February 5, 2021, with two doses of injection for each person, each dose given at an interval of 28 days.

The emergency use permit, according to the Head of BPOM Penny Lukito, is based on the results of monitoring of the phase I and II clinical trial processes in China, which are given to residents over 60 years of age.

The results of the clinical trial in China, of the 400 elderly people who were given the Coronavac vaccine injection, had an immune level of up to 97.96 percent after the second injection.

The BPOM also considered the results of the Phase III clinical trial in Brazil, which showed that vaccine injections to 609 elderly people generally had mild side effects, namely pain, nausea, fever, swelling, redness of the skin, and headaches.